A randomized open-label, phase I/II, CodeBreak 100 study was conducted in 733 patients with KRAS G12C mutation advanced solid tumors and in a subgroup of 126 NSCLC patients pretreated with standard therapies. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.